• Latest
  • Trending
  • All
  • News
  • Business
  • Lifestyle
Omicron Variant Neutralized by Third Pfizer COVID Shot, Company Says

Omicron Variant Neutralized by Third Pfizer COVID Shot, Company Says

December 8, 2021

Border crossings dip to lowest levels in 55 years following calls for reform by Democrats.

February 5, 2026

Vance and Rubio warmly welcome American winter Olympians in Italy.

February 5, 2026

Republican firebrand calls for rescinding taxpayer benefits given to immigrants by Trump agencies.

February 5, 2026

Pro-life advocates uncover Biden-era FDA policy causing 500 daily abortions, urge Trump to take action now!

February 5, 2026

11 Democrats vying to maintain control of blue-leaning seat as GOP House majority hangs in the balance.

February 5, 2026

Georgia GOP Rep Barry Loudermilk announces retirement, contributing to growing trend of House departures

February 5, 2026

Georgia GOP Rep Barry Loudermilk joins growing number of House members retiring

February 5, 2026

Georgia GOP Rep Barry Loudermilk announces retirement, joining a wave of House departures.

February 5, 2026

Georgia GOP Rep Barry Loudermilk announces retirement, contributing to growing number of House departures

February 5, 2026

Georgia GOP Rep Barry Loudermilk announces retirement, contributing to growing trend of House members stepping down.

February 5, 2026

Georgia GOP Rep Barry Loudermilk announces retirement, joining the growing trend of House members stepping down

February 4, 2026

Popular Georgia GOP Rep Barry Loudermilk announces retirement, joining increasing number of House members stepping down

February 4, 2026
  • Trending Topics:    
  • 2024 Election
  • Joe Biden
  • Donald Trump
  • Congress
  • Faith
  • Sports
  • Immigration
Thursday, February 5, 2026
IJR
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Headlines
No Result
View All Result
IJR
No Result
View All Result
Home News

Omicron Variant Neutralized by Third Pfizer COVID Shot, Company Says

by Madison Summers
December 8, 2021 at 8:41 am
in News
251 5
0
Omicron Variant Neutralized by Third Pfizer COVID Shot, Company Says

A syringe is filled with a first dose of the Pfizer Covid-19 vaccine at a mobile vaccination clinic during a back to school event offering school supplies, Covid-19 vaccinations, face masks, and other resources for children and their families at the Weingart East Los Angeles YMCA in Los Angeles, California on August 7, 2021. (Photo by Patrick T. FALLON / AFP) (Photo by PATRICK T. FALLON/AFP via Getty Images)

498
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

Pfizer and BioNTech’s preliminary studies found that a third shot against COVID-19 neutralized the Omicron variant.

The company made the announcement on Wednesday, writing that two doses of the vaccine “significantly reduced neutralization titers.” And, results “from an initial laboratory study” demonstrate “that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses.”

Albert Bourla, Chairman and Chief Executive Officer, Pfizer, wrote in a statement, “Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine.”

“Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19,” he added.

Additionally, Ugur Sahin, M.D., CEO and Co-Founder of BioNTech, said in a statement:

“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant. Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”

The press release also notes that the company has been working on an Omicron-specific COVID-19 vaccine since November 25.

It reads, “The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval.”

Over a 14-day change, there has been a 27% increase in COVID cases reported in the U.S., as well as an increase in hospitalizations and deaths related to the coronavirus, according to The New York Times.

Sixty percent of all Americans are fully vaccinated against COVID-19, according to the U.S. Centers for Disease Control and Prevention. Twenty-four percent of all Americans who are fully vaccinated have received a booster shot, as of data collected since August 13.

President Joe Biden said on November 29, “This variant is a cause for concern, not a cause for panic,” adding, “We have the best vaccine in the world, the best medicines, best scientists, and we’re learning more every single day. We’ll fight this variant with scientific and knowledgeable actions and speed, not chaos and confusion.”

The president announced on December 2 new actions the administration is taking to combat the Delta and Omicron variants. It includes “calling on employers to follow the federal government’s lead and provide paid time off to their employees to get boosted,” expanding free at-home testing, stronger protocols for international travel, and more.

Tags: Coronavirus OutbreakU.S. Newsworld news
Share199Tweet125
Madison Summers

Madison Summers

IJR, Managing Editor

Join Over 6M Subscribers

We’re organizing an online community to elevate trusted voices on all sides so that you can be fully informed.





IJR

    Copyright © 2024 IJR

Trusted Voices On All Sides

  • About Us
  • GDPR Privacy Policy
  • Terms of Service
  • Editorial Standards & Corrections Policy
  • Subscribe to IJR

Follow Us

No Result
View All Result
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Headlines

    Copyright © 2024 IJR

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Thanks for reading IJR

Create your free account or log in to continue reading

Please enter a valid email
Forgot password?

By providing your information, you are entitled to Independent Journal Review`s email news updates free of charge. You also agree to our Privacy Policy and newsletter email usage